In today’s session Puma Biotechnology Inc (PBYI) recorded an unusually high (150) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious PBYI decrease. With 150 contracts traded and 2004 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: PBYI161021P00055000 closed last at: $1.6 or 3.2% up. The stock decreased 2.56% or $1.64 during the last trading session, hitting $62.54. About 753,031 shares traded hands. Puma Biotechnology Inc (NYSE:PBYI) has risen 29.54% since March 2, 2016 and is uptrending. It has outperformed by 20.29% the S&P500.
Analysts await Puma Biotechnology Inc (NYSE:PBYI) to report earnings on November, 14. They expect $-2.05 earnings per share, down 9.63% or $0.18 from last year’s $-1.87 per share. After $-2.05 actual earnings per share reported by Puma Biotechnology Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Puma Biotechnology Inc (NYSE:PBYI) Ratings Coverage
Out of 6 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Puma Biotechnology Inc has been the topic of 13 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Citigroup initiated the stock with “Neutral” rating in Thursday, September 3 report. Stifel Nicolaus upgraded the stock to “Buy” rating in Wednesday, September 21 report. The stock of Puma Biotechnology Inc (NYSE:PBYI) earned “Outperform” rating by Credit Suisse on Thursday, September 22. The rating was maintained by UBS on Monday, April 11 with “Buy”. The company was maintained on Tuesday, March 29 by JP Morgan. The company was maintained on Tuesday, March 29 by Credit Suisse. The stock of Puma Biotechnology Inc (NYSE:PBYI) has “Buy” rating given on Tuesday, March 29 by Citigroup. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, March 29. The firm has “Overweight” rating by JP Morgan given on Thursday, August 27. The company was initiated on Thursday, January 21 by Credit Suisse.
Insitutional Activity: The institutional sentiment increased to 1.21 in Q2 2016. Its up 0.18, from 1.03 in 2016Q1. The ratio is positive, as 24 funds sold all Puma Biotechnology Inc shares owned while 24 reduced positions. 18 funds bought stakes while 40 increased positions. They now own 31.26 million shares or 4.53% more from 29.91 million shares in 2016Q1.
Northern Mngmt Limited Company last reported 16,288 shares in the company. Moreover, Partner Investment Mngmt L P has 1.11% invested in Puma Biotechnology Inc (NYSE:PBYI) for 22,740 shares. Moreover, Geode Cap Mgmt Limited Liability Company has 0% invested in Puma Biotechnology Inc (NYSE:PBYI) for 146,950 shares. Rock Springs Cap Mngmt L P reported 33,000 shares or 0.07% of all its holdings. The Colorado-based Public Employees Retirement Association Of Colorado has invested 0% in Puma Biotechnology Inc (NYSE:PBYI). Fincl Bank Of America Corporation De holds 0% or 266,479 shares in its portfolio. Nationwide Fund Advisors holds 0% or 16,108 shares in its portfolio. Partner Fund Lp accumulated 1.47 million shares or 1.32% of the stock. Plante Moran Fincl Advisors reported 1,500 shares or 0.03% of all its holdings. Credit Suisse Ag holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 60,589 shares. Profund Ltd Limited Liability Company has 0.02% invested in the company for 12,706 shares. Diam Com Limited accumulated 172,207 shares or 0.08% of the stock. Fmr Limited Liability last reported 4.87 million shares in the company. Vanguard holds 0% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 1.93M shares. Tekla Capital Mngmt Ltd Liability Corporation holds 0.32% of its portfolio in Puma Biotechnology Inc (NYSE:PBYI) for 260,200 shares.
Puma Biotechnology, Inc. is a biopharmaceutical firm that focuses on the development and commercialization of products for the treatment of cancer. The company has a market cap of $1.95 billion. The Firm focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 ), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. It currently has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.